This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Drugs Generic Drugs Sales 
Bio Pharma Dive
AUGUST 25, 2022
After reviewing multiple options including a possible sale, the Swiss drugmaker said spinning off Sandoz would give the division “greater freedom to operate” and capitalize on newly growing sales.
284 
Pharmaceutical Technology
SEPTEMBER 15, 2022
As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.
272
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
OCTOBER 26, 2021
The generic drug unit has struggled in recent years, while Novartis has moved to focus more narrowly on higher-margin branded medicines.
176 
Bio Pharma Dive
JULY 18, 2023
The pharma company, which will soon split off its generic drug unit, plans to repurchase up to $15 billion of its shares through the end of 2025.
130 
Pharmaceutical Technology
MAY 3, 2023
Since 2015, the US Food and Drug Administration (FDA) has approved more than 450 “first generics” or the first generic equivalent for a branded drug. These medicines comprise about 10% of all generics approved each year.
246 
Drug Channels
OCTOBER 18, 2022
The biosimilar boom for provider-administered drugs continues to accelerate. Some major biological reference products have now lost a majority of their unit sales to their biosimilars. Below, we share our estimates for wholesalers’ gross margins for brand-name, generic, and biosimilar drugs. drug distribution.
97 
Pharmaceutical Technology
JULY 15, 2022
CivicaRx is a non-profit generic drug company producing affordable insulin biosimilars in collaboration with the Juvenile Diabetes Research Foundation (JDRF). Making low-cost insulin widely available will benefit anyone who struggles to afford this drug,” he adds. In-house manufacturing the norm.
328 
Camargo
NOVEMBER 11, 2020
When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product.
242 
Pharmaceutical Technology
NOVEMBER 21, 2022
Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 billion) in total sales in 2021 and is expected to grow 1.1% Among the 37 member companies, 17 of them are overseas companies and 20 of them are Japanese companies with a 10%+ overseas pharma sales ratio.
173 
Pharmacy Checkers
FEBRUARY 5, 2021
The Rand Corporation has released an impressive study showing that brand name drugs cost far more in the United States than in other countries – on average 344% more. For those of you looking for a methodologically strong analysis of international drug prices and a history of related studies, this is the report for you.
97 
Pharmaceutical Technology
DECEMBER 20, 2022
The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. Despite a drop in sales from Regeneron’s COVID-19 antibody, REGEN-COV, due to ineffectiveness against the Omicron variant, the company experienced record US sales of $1.63 and 10%, respectively.
130 
Pharmaceutical Technology
OCTOBER 5, 2008
’ Generic drug renaissance Shionogi’s acquisition of Sciele was partly due to the US business experience of Shionogi’s chief executive, Isao Teshirogi. ” The move, which came in June, also gives Japanese drugs maker Daiichi Sankyo a foothold in the Indian market through Ranbaxy’s location. .”
100 
pharmaphorum
NOVEMBER 8, 2021
The largest left-leaning party in Switzerland said that national ownership of Sandoz would democratise the production and development of new medicines, maintain a stable supply of affordable drugs, and allow less profitable R&D to be carried out with state support. billion in the first nine months of the year, and were down 17% in the US.
116 
pharmaphorum
MARCH 5, 2021
The European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company illegally delayed launches and use of generic versions of its blockbuster multiple sclerosis drug Copaxone. In the end it wasn’t enough and sales last year were $213 million, a fraction of the $4.3
98 
Pharmaceutical Technology
NOVEMBER 21, 2022
Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 billion) in total sales in 2021 and is expected to grow 1.1% Among the 37 member companies, 17 of them are overseas companies and 20 of them are Japanese companies with a 10%+ overseas pharma sales ratio.
130 
Pharmacy Checkers
DECEMBER 5, 2019
A new Chinese law (in effect as of December 1, 2019) makes third-party online platform medicine sales legal, appropriately ends a draconian definition of counterfeit drugs, and effectively decriminalizes personal drug importation, but with a lot of gray! Decriminalizing Personal Drug Importation and Redefining “Counterfeit”.
64 
Pharmaceutical Technology
JANUARY 6, 2023
In this most recent settlement, the drug company faced allegations of colluding with the generics company Par Pharmaceuticals to violate antitrust laws. Novartis has also been on the receiving end of litigation with the Greek health ministry, academic institutes, and more, engaging the drug company in other legal disputes.
242 
pharmaphorum
JULY 29, 2021
Mylan’s Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi’s drug, but only if specifically prescribed for a patient. The post FDA okays Mylan insulin drug as first ‘interchangeable’ biosimilar appeared first on.
98 
Pharmaceutical Technology
SEPTEMBER 15, 2022
Various factors have contributed to the need and growth of API chemical suppliers such as rising healthcare expenditure, increasing disposable incomes, growing geriatric population, increasing incidence of chronic diseases, patent expiration of blockbuster drugs, increased consumption of generic drugs, and intervention of the new generation APIs.
100 
Pharma in Brief
FEBRUARY 8, 2024
On January 26, 2024, Health Canada published a Notice concerning its application of the definition of Canadian Reference Product ( CRP ) in the Food and Drug Regulations ( Regulations ). For instance, the generic drug must be “the pharmaceutical equivalent of the [CRP]” and be “bioequivalent with the [CRP]”.
52 
pharmaphorum
JULY 29, 2021
The UK has levied another big fine for anticompetitive activity in the pharma market in a fortnight, with Advanz Pharma and former owners on the hook for more than £100 million ($140 million) after increasing the price of a thyroid disease drug by 1,110% over an eight-year period. ” Advanz itself was directly fined £40.9
98 
Pharma in Brief
AUGUST 9, 2021
On July 31, 2021, Health Canada published a Notice of Intent outlining its plan to amend the Food and Drug Regulations ( FDR ) and the Medical Devices Regulations in the spring of 2022. The following is a general summary of some of the highlights from the proposed amendments discussed in the Notice of Intent. Biologic Drugs.
98 
pharmaphorum
AUGUST 20, 2020
Shares in Teva were down sharply this week after the US Department of Justice filed a complaint that the company paid illegal kickbacks to patient groups to boost sales of its multiple sclerosis drug Copaxone (glatiramer). The allegation is that Teva’s subsidiaries Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc.
115 
Camargo
DECEMBER 9, 2020
Evergreening Orphan Drugs May Be Over. The Orphan Drug Act of 1983 provides market exclusivity for drugs intended to treat conditions affecting fewer than 200,000 patients in the US. This effectively “evergreens” the product, preventing generic competition. Unapproved Drug Initiative Ends.
140 
Pharmaceutical Technology
SEPTEMBER 7, 2022
The list includes companies offering various products and services, including but not limited to: · Over-the-counter drugs. Prescription refill and generic drug programmes. Speciality care. Compounding services. Pharmacogenetics testing. Filling services. Proprietary pharmaceutical, nutraceutical, and cosmeceutical products.
113 
pharmaphorum
SEPTEMBER 9, 2022
Novo Nordisk can be credited with re-invigorating the market for obesity drug therapies with its GLP-1 agonist therapies – Saxenda (liraglutide) and Wegovy (semaglutide) – which collectively saw sales increase 84% to $950 million, despite some supply constraints for Wegovy. billion in 2025.
113 
XTalks
JANUARY 20, 2025
Key benefits included the addition of Celgenes blockbuster drug Revlimid (lenalidomide), a cornerstone of its oncology portfolio, and access to innovative CAR-T therapies such as Abecma (idecabtagene vicleucel). While the deal required regulatory divestitures, including the sale of Otezla (apremilast) to Amgen for $13.4
104 
pharmaphorum
FEBRUARY 2, 2022
If approved, the new drug would be sold through the sales channels set up by Pharming for Ruconest (conestat alfa), its treatment for rare disease hereditary angioedema (HAE) which is facing increasing competition in the marketplace from drugs like Takeda’s Takhzyro (lanadelumab).
52 
Druggist
SEPTEMBER 30, 2020
Buscopan and mebeverine are two common drugs used for symptomatic treatment of irritable bowel syndrome (IBS). Both drugs can be prescribed by a doctor or purchased over the counter from pharmacies and in case of Bucopa IBS relief from supermarkets. Buscopan vs Mebeverine lists similarities and differences between both drugs.
98 FDA Law Blog
JUNE 16, 2023
Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drug pricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers. We address each below.
45 
pharmaphorum
NOVEMBER 2, 2020
Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the condition that the two companies divest various generic drug products. Once formed, Viatris will be a generics behemoth with annual sales of around $19 to $20 billion and operations in 165 markets around the word.
FDA Law Blog
JUNE 2, 2022
Since 1984, generic drugs have been approved under ANDAs pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA); before 1984, no formal mechanism for an ANDA existed so FDA used sections 505(b) and 505(c) to approve follow-on drugs based on the Agency’s previous findings of safety and efficacy.
52 
Pharmacy Checkers
DECEMBER 26, 2019
Health System By Lowering Drug Prices, Reducing, Out-of-Pocket Costs and Improving the Medicare Benefit”. Health System By Lowering Drug Prices, Reducing, Out-of-Pocket Costs and Improving the Medicare Benefit”. Its mission is to end the crisis of high prescription drug prices in America, and to do so on a bipartisan basis.
73 
FDA Law Blog
MARCH 5, 2024
By Faraz Siddiqui — Last Friday, the Delaware District Court rejected AstraZeneca’s lawsuit against the Medicare Drug Price Negotiation Program enacted under the Inflation Reduction Act (IRA) and CMS’s guidance implementing it. Opinion at 17. contradicts the plain text of the statute and therefore must be set aside.” see also 42 U.S.C.
pharmaphorum
NOVEMBER 26, 2020
We were the first company to commit to keeping prices stable for drugs seen as essential treatments for COVID-related symptoms. “As In addition, we have made a commitment to provide 15 drugs to low-income countries at cost.”. As an industry, we will have to be more honest with ourselves. Remote pharma. About the interviewee.
111 
pharmaphorum
JANUARY 25, 2022
Mark Cuban, billionaire owner of the Dallas Mavericks basketball team, just got involved in the online pharmacy business, promising to “shield consumers from inflated drug prices.” If you are looking for lower pricing on your generic drug purchases, go to [link] and sign up ! All drugs are priced at cost plus 15% !
52 
pharmaphorum
MARCH 16, 2022
Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca’s top-selling respiratory drug Symbicort, although launch plans remain uncertain for now. Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1
59 
The Pharma Data
JANUARY 27, 2021
Construction of commercial drug manufacturing facility in Germany. Psychedelic transdermal and sublingual drug formulation development. Vektor will position itself for commercial manufacturing, pipeline development and drug formulations for critical mental health conditions.
52 
pharmaphorum
JUNE 3, 2021
The FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly genericised market. It has however been contraindicated in people taking opioids. In its favour?
52 
Pharmaceutical Technology
JULY 10, 2008
As the blockbuster drugs of the 90s that earned the industry billions reach their patent shelf lives, pharmaceutical companies require new medicines to sustain an estimated $157bn worth of sales. The report says the infrastructure around regulators vendors and the support industry will have to significantly change.
100 
The Pharma Data
DECEMBER 28, 2020
Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. This further highlights Amphastar’s considerable abilities to bring complex generic drugs to the market, and more specifically, our strong peptide capabilities.”
Pharma in Brief
JUNE 21, 2020
They include: (1) new factors for assessing excessive pricing, (2) new powers to collect information regarding these factors, (3) new obligations to report indirect price adjustments, (4) risk-based reporting obligations for OTC and generic drugs, and (5) a revised list of international price comparator countries (the PMPRB11 ).
40 
The Pharma Data
DECEMBER 4, 2021
“The launch of our first-to-market authorized generic version of Epiduo® Forte Gel in the U.S. provides patients with another important treatment option,” said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA. Currently, 1 in 11 generic prescriptions dispensed in the U.S. IMPORTANT SAFETY INFORMATION.
52 
Creogenic Pharma
APRIL 15, 2023
India is a major player in the global pharmaceutical industry, accounting for almost 20% of the export volume of generic drugs worldwide. We understand the challenges and complexities of meeting the standards set by drug authorities and take them into consideration in all our operations.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content